Vaccine access inequity remains one of the most persistent structural failures exposed by the COVID-19 pandemic, and addressing it requires not just political will but locally developed, logistically viable candidates. A trial protocol published in JMIR Research Protocols outlines a phase 1/2a evaluation of TANCoV-1.3.20, an intranasal SARS-CoV-2 vaccine candidate developed for testing within Tanzania — a development that represents a meaningful step toward African-led vaccine science.
The TANCoV-1 trial is a double-blinded, randomized controlled study enrolling 150 SARS-CoV-2-negative healthy adults across Dar es Salaam and Mbeya. Participants are randomized 1:1:1 across three arms: a 100 µL dose with booster, a 100 µL dose without booster, and a 200 µL dose without booster, with each group containing equal intervention and control subgroups. Primary endpoints focus on safety and tolerability, while secondary objectives assess both humoral and cellular immune response profiles and dose-dependent immunogenicity gradients. The intranasal delivery route distinguishes this candidate from most approved COVID vaccines, which rely on intramuscular injection.
Mucosal vaccine delivery via nasal administration has long attracted scientific interest because it may stimulate secretory IgA responses at the respiratory mucosa — the primary site of SARS-CoV-2 entry — potentially offering a distinct immunological advantage over systemic injection alone. Several intranasal COVID vaccine efforts have been explored globally, including candidates in India and China, with mixed early-phase results. What makes this protocol particularly noteworthy is its Sub-Saharan African origin and design intent: cold-chain dependencies and needle-based administration have historically complicated vaccine rollout in low-resource settings. A nasal vaccine that performs well in African populations could meaningfully shift those logistics. That said, this is a published protocol, not results — the trial is at the design and planning stage. Efficacy data, tolerability profiles, and immunogenicity readouts are all forthcoming. Phase 1/2a trials are primarily safety-scoping exercises, and the leap from promising early-phase data to deployable vaccine is substantial. Progress should be tracked but expectations calibrated accordingly.